Alliance A091605 (Merkel Cell Carcinoma) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to see if the study drug MK-3475 (pembrolizumab) and radiation is better, the same, or worse than MK-3475 (pembrolizumab) without radiation.
Merkel Cell Carcinoma
Who Can Participate in the Study?
- Have Merkel Cell Carcinoma that is advanced or metastatic
- Have no prior immunotherapy for advanced or metastatic disease
- Have no other active cancer
- Are not pregnant or nursing
What is Involved?
If you choose to join this study, you will:
Be assigned to a study group (like a flip of a coin) to either:
- Get the study drug plus radiation
-- Get the radiation during the first 21 days of MK-3475 (pembrolizumab) only
-- Get radiation treatment that will include a planning session and 3 treatments
-- Be followed closely by your study doctor for side effects and your condition every 3 months for five years after you have finished the MK-3475 (pembrolizumab)
- Get the study drug alone
The study drug MK-3475 (pembrolizumab) will be given through a vein in your arm for up to two years as long as it is helping treat your cancer.